Innoviva Inc. Stock
Innoviva Inc. Stock
There is an upward development for Innoviva Inc. compared to yesterday, with an increase of €0.30 (1.720%).
Currently there is a rather positive sentiment for Innoviva Inc. with 5 Buy predictions and 0 Sell predictions.
With a target price of 24 € there is a positive potential of 35.59% for Innoviva Inc. compared to the current price of 17.7 €.
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | 1.720% | -3.333% | -0.571% | -2.793% | 5.455% | 41.463% | 103.509% |
| Pacira Pharmaceuticals | 1.980% | 1.000% | 12.849% | 13.483% | 9.189% | -53.670% | -58.264% |
| Rockwell Medical Inc. | -7.730% | 3.154% | -3.416% | -58.916% | -58.631% | -9.838% | -92.418% |
| Twist Bioscience Corp | -1.080% | 7.737% | 5.966% | -44.491% | -39.405% | 11.129% | -76.316% |
Comments
Innoviva (NASDAQ:INVA) had its price target raised by analysts at Cantor Fitzgerald from $29.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
News
Innoviva (INVA) Q2 Sales Jump 64%
Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share
